Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 5/2014

01.05.2014 | PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Patient Involvement in Outcome Measures for Psoriatic Arthritis

verfasst von: William Tillett, Ade Adebajo, Mel Brooke, Willemina Campbell, Laura C. Coates, Oliver FitzGerald, Laure Gossec, Philip Helliwell, Sarah Hewlett, Jana James, Patricia Minnock, Aisling Reast, Dennis O’Sullivan, Maarten de Wit, Neil McHugh

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis with a varied clinical phenotype. There has been considerable international collaboration over recent years to develop and prioritise appropriate disease domains and outcome measures to capture all aspects of this complex disease. It has been recognised that patient-reported measures and physician assessments are complementary and, when used together, allow an improved reflection of disease burden. Taking this concept one step further, the experience in rheumatoid arthritis has demonstrated benefits of incorporating the patient perspective in the development of outcome measures. We report a systematic review demonstrating (1) that there has been little incorporation of the patient perspective in the development of outcome measures and domains in PsA, (2) the proceedings from the preliminary patient involvement in outcome measures for PsA (PIOMPSA) meetings, and (3) a proposed roadmap for improving patient involvement.
Literatur
1.
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63 Suppl 11:S64–85.CrossRef
2.
Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34(5):1167–70.PubMed
3.
Taylor WJ. Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods. Ann Rheum Dis. 2005;64 Suppl 2:ii110–2.PubMedCentralPubMed
4.•
Palominos PE, Gaujoux-Viala C, Fautrel B, et al. Clinical outcomes in psoriatic arthritis: a systematic literature review. Arthritis Care Res. 2012;64(3):397–406. A systematic review demonstrating great heterogeneity in the reporting of outcomes in PsA clinical trials and the need for consensus on the reporting of PsA domains. CrossRef
5.
Berkanovic E, Hurwicz ML, Lachenbruch PA. Concordant and discrepant views of patients’ physical functioning. Arthritis Care Res Official J Arthritis Health Prof Assoc. 1995;8(2):94–101.CrossRef
6.
Studenic P, Radner H, Smolen JS, et al. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64(9):2814–23.PubMedCrossRef
7.•
Dandorfer SW, Rech J, Manger B, et al. Differences in the patient’s and the physician’s perspective of disease in psoriatic arthritis. Semin Arthritis Rheum. 2012;42(1):32–41. A study demonstrating the discrepancies between physician and patient perspectives of PsA. PubMedCrossRef
8.
9.
Kirwan JR, Fries JF, Hewlett SE, et al. Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes. J Rheumatol. 2011;38(8):1711–5.PubMedCrossRef
10.
Kirwan JR, Fries JF, Hewlett S, et al. Patient perspective: choosing or developing instruments. J Rheumatol. 2011;38(8):1716–9.PubMedCrossRef
11.
de Wit M, Abma T, Koelewijn-van Loon M, et al. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ. 2013;3(5). doi:10.​1136/​bmjopen-2012-002241.
12.••
de Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis. 2011;70(5):722–6. The EULAR recommendations for incorporating the patients’ perspective in scientific research developed by patient partners, rheumatologists and allied health professionals. PubMedCrossRef
13.
Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis–progress at OMERACT 7. J Rheumatol. 2005;32(11):2250–6.PubMed
14.
NIHR. Briefing notes for researchers: public involvement in NHS, public health and social care research. Eastleigh: Involve; 2012.
15.
McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63(2):162–9.PubMedCentralPubMedCrossRef
16.
Stamm TA, Nell V, Mathis M, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum. 2007;57(3):487–94.PubMedCrossRef
17.
MacKenzie H, Thavaneswaran A, Chandran V, et al. Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires. J Rheumatol. 2011;38(12):2619–24.PubMedCrossRef
18.••
Gossec LDWM, Heiberg T, Maccarone M, Balanescu A, Balint P, Dora Niedermayer D, et al. Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. A 13-country EULAR initiative with involvement of patient research partners from each country. Madrid: EULAR; 2013. p. OP0111. The development and preliminary validation of the PsA impact of disease (PsAID) project. This novel measure has been developed in close collaboration with patient partners.
19.
Hewlett S, Sanderson T, May J, et al. ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count–an international patient perspective on flare where medical help is sought. Rheumatology (Oxford). 2012;51(1):69–76.CrossRef
20.
Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol. 2007;34(6):1302–6.PubMed
21.•
Bingham 3rd CO, Alten R, de Wit MP. The importance of patient participation in measuring rheumatoid arthritis flares. Ann Rheum Dis. 2012;71(7):1107–9. An editorial concisely describing the rational and evidence for incorporating the patient perspective in measuring rheumatoid arthritis flares. PubMedCrossRef
22.
Blackmore MG, Gladman DD, Husted J, et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol. 1995;22(5):886–93.PubMed
23.
Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum. 1999;42(10):2220–30.PubMedCrossRef
24.
Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(2):151–8.PubMedCrossRef
25.
Husted JA, Gladman DD, Long JA, et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol. 1995;13(4):439–43.PubMed
26.
Husted JA, Tom BD, Farewell VT, et al. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum. 2005;53(3):404–9.PubMedCrossRef
27.
Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum. 2007;56(3):840–9.PubMedCrossRef
28.
Leung YY, Tam LS, Kun EW, et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol. 2008;35(8):1613–21.PubMed
29.
Brodszky V, Pentek M, Balint PV, et al. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand J Rheumatol. 2010;39(4):303–9.PubMedCrossRef
30.
Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461–5.PubMedCrossRef
31.
Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol. 2010;37(5):1024–8.PubMedCrossRef
32.
Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum. 2004;50(10):3296–305.PubMedCrossRef
33.
Daltroy LH, Larson MG, Roberts NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol. 1990;17(7):946–50.PubMed
34.
Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol. 1997;24(3):511–7.PubMed
35.
Taylor WJ, McPherson KM. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum. 2007;57(5):723–9.PubMedCrossRef
36.
Leung YY, Ho KW, Zhu TY, et al. Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology (Oxford). 2010;49(8):1495–501.CrossRef
37.
Kvamme MK, Kristiansen IS, Lie E, et al. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2010;37(1):26–31.PubMedCrossRef
38.
Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.PubMedCentralPubMedCrossRef
39.
Husted J, Gladman DD, Farewell VT, et al. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic Arthritis. J Rheumatol. 1996;23(6):1015–9.PubMed
40.
Husted J, Gladman DD, Long JA, et al. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol. 1996;23(11):1932–7.PubMed
41.
Duffy CM, Watanabe Duffy KN, Gladman DD, et al. The utility of the arthritis impact measurement scales for patients with psoriatic arthritis. J Rheumatol. 1992;19(11):1727–32.PubMed
42.
Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28(8):1842–6.PubMed
43.
Singh JA, Strand V. Health care utilization in patients with spondyloarthropathies. Rheumatology (Oxford). 2009;48(3):272–6.CrossRef
44.
Healy PJ, Helliwell PS. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. J Rheumatol. 2008;35(7):1359–61.PubMed
45.
Nichol MB, Margolies JE, Lippa E, et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. PharmacoEconomics. 1996;10(6):644–53.PubMedCrossRef
46.
Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898–903.PubMedCrossRef
47.
Leung YY, Ho KW, Zhu TY, et al. Construct validity of the modified numeric rating scale of patient global assessment in psoriatic arthritis. J Rheumatol. 2012;39(4):844–8.PubMedCrossRef
48.
Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise–the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34(8):1740–5.PubMed
49.
Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.PubMedCrossRef
50.
Louden BA, Pearce DJ, Lang W, et al. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.PubMed
51.
Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106(1):183–6.PubMedCrossRef
52.
Carlin CS, Feldman SR, Krueger JG, et al. A 50 % reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859–66.PubMedCrossRef
53.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.PubMedCrossRef
54.
Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948–53.PubMedCrossRef
55.
Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise–the INSPIRE study: I. Assessment of spinal measures. J Rheumatol. 2007;34(8):1733–9.PubMed
56.
Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol. 2005;32(9):1745–50.PubMed
57.
Leung YY, Ho KW, Tam LS, et al. Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. Clin Rheumatol. 2011;30(9):1157–62.PubMedCrossRef
58.
Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum. 2009;61(3):386–92.PubMedCrossRef
59.
Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 2004;51(3):311–5.PubMedCrossRef
60.
Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, et al. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res. 2010;62(1):78–85.CrossRef
61.
Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis. 2010;69(12):2160–4.PubMedCrossRef
62.
Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–12.PubMedCrossRef
63.
Aktan S, Ilknur T, Akin C, et al. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2007;32(2):141–4.PubMedCrossRef
64.
Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–9.PubMed
65.
Maejima H, Taniguchi T, Watarai A, et al. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol. 2010;49(8):901–6.PubMedCrossRef
66.
Gladman DD, Strand V, Mease PJ, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis. 2005;64 Suppl 2:ii115–6.PubMedCentralPubMed
67.
Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–7.PubMedCrossRef
68.
FitzGerald O, Helliwell P, Mease P, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71(3):358–62.PubMedCrossRef
69.
Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69(3):546–9.PubMedCrossRef
70.
Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441–7.PubMedCrossRef
71.
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48–53.PubMedCrossRef
72.
Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. 2010;62(7):970–6.CrossRef
73.
Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62(7):965–9.CrossRef
74.
Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol. 2010;37(9):1892–7.PubMedCrossRef
75.
Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis (PsA). II: further considerations and a proposal–the PsA joint activity index. J Rheumatol. 2010;37(12):2559–65.PubMedCrossRef
76.
Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986–91.PubMedCrossRef
Metadaten
Titel
Patient Involvement in Outcome Measures for Psoriatic Arthritis
verfasst von
William Tillett
Ade Adebajo
Mel Brooke
Willemina Campbell
Laura C. Coates
Oliver FitzGerald
Laure Gossec
Philip Helliwell
Sarah Hewlett
Jana James
Patricia Minnock
Aisling Reast
Dennis O’Sullivan
Maarten de Wit
Neil McHugh
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 5/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0418-7

Weitere Artikel der Ausgabe 5/2014

Current Rheumatology Reports 5/2014 Zur Ausgabe

VASCULITIS (LR ESPINOZA, SECTION EDITOR)

Non-Infectious Cryoglobulinemia Vasculitis (CryoVas): Update on Clinical and Therapeutic Approach

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis

ANTIPHOSPHOLIPID SYNDROME (D ERKAN, SECTION EDITOR)

New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/PT) Antibodies

IMAGING (P CONAGHAN, SECTION EDITOR)

Heading Toward a Modern Imaging Approach in Juvenile Idiopathic Arthritis

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise